Back to Search
Start Over
Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review.
- Source :
-
Journal of gastrointestinal and liver diseases : JGLD [J Gastrointestin Liver Dis] 2011 Sep; Vol. 20 (3), pp. 293-8. - Publication Year :
- 2011
-
Abstract
- Background: Patients with HCV liver cirrhosis are a category difficult to treat. The aim of this study was to establish the sustained virological response (SVR) rates in HCV patients with liver cirrhosis treated with standard of care therapy (Pegylated Interferon and Ribavirin for 48 weeks in genotypes 1 and 4 and 24 weeks in genotypes 2 and 3).<br />Methods: Searching the PubMed, Medline, Lilacs, Scopus, Ovid and Medscape databases we identified all the articles published until February 2011 that included only HCV cirrhotic patients. These studies evaluated the SVR after standard of care treatment: Pegylated Interferon alpha 2a (doses ranging between 135-180 µg/week) or Pegylated Interferon alpha 2b (1 or 1.5 µg/kg/week) and Ribavirin (doses ranging between 800-1200 mg/day). We used the following key words: HCV, liver cirrhosis, sustained virological response (SVR).<br />Results: The overall SVR rate was 33.3% (95%CI-confidence interval=30.6-36.2%). SVR was significantly higher in patients with genotypes 2 and 3 (422 patients) as compared to those with genotypes 1 and 4 (692 patients): 55.4% (95%CI=50.7-60.1) versus 21.7% (95%CI=18.7-25), p < 0.0001.<br />Conclusion: The overall SVR rate in cirrhotic patients treated with standard of care therapy is 33.3%, but lower in cases affected by genotypes 1 and 4 (21.6%) which makes them a priority regarding the development of more potent drugs for effective treatment.
- Subjects :
- Adult
Aged
Female
Hepatitis C, Chronic complications
Hepatitis C, Chronic virology
Humans
Interferon alpha-2
Interferon-alpha therapeutic use
Male
Middle Aged
Polyethylene Glycols therapeutic use
Quality-Adjusted Life Years
Recombinant Proteins therapeutic use
Ribavirin therapeutic use
Antiviral Agents therapeutic use
Hepatitis C, Chronic drug therapy
Liver Cirrhosis etiology
Subjects
Details
- Language :
- English
- ISSN :
- 1842-1121
- Volume :
- 20
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Journal of gastrointestinal and liver diseases : JGLD
- Publication Type :
- Academic Journal
- Accession number :
- 21961098